

## Learner Notification

### MED Learning Group

#### Improving Care for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Tips for the Practicing Community-based Clinician

November 29, 2023 – November 29, 2024

Online

### Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc. and Sanofi

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

### Objectives - After Attending This Program You Should Be Able To

1. Identify strategies to manage CRSwNP that are aligned with evidence-based guidelines.
2. Discuss the clinical evidence for novel, emerging therapeutic agents for the treatment of CRSwNP.
3. Describe strategies to effectively select treatment based on patient-specific factors and expert guidance.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Felecia	Beachum	NA
Kathleen M.	Buchheit	AstraZeneca, Sanofi, Genentech, Regeneron, GlaxoSmithKline: Consultant, UpToDate: Royalties
Cecelia	Damask	GlaxoSmithKline, Sanofi/Regeneron: Advisory Board, GlaxoSmithKline, OptiNose, Sanofi/Regeneron: Speakers Bureau, AstraZeneca, GlaxoSmithKline, OptiNose, Sanofi/Regeneron: Clinical Research
Naomi	De Brito	NA
Matthew	Frese	NA
Christina	Gallo	NA
Debra	Gordon	NA
Stella E.	Lee	AstraZeneca, GlaxoSmithKline, Genentech, Lyra Therapeutics, OptiNose, Sanofi/Regeneron: Consultant

Anju T.	Peters	AstraZeneca, GlaxoSmithKline, Merck, OptiNose, Regeneron Pharmaceuticals, Sanofi: Consultant, AstraZeneca, Merck, Regeneron Pharmaceuticals, Sanofi: Research, UpToDate: Royalties
Jo	Shultz	NA
Whitney W.	Stevens	Regneron, GlaxoSmithKline, Melinta Therapeutics: Consultant
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)